Sa’diyah, Khalimatus (2019) SYSTEMATIC REVIEW: ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN FOLFOX-6 DAN FOLFOX-6 KOMBINASI BEVACIZUMAB® PADA PASIEN KANKER KOLOREKTAL METASTASE (mCRC) DARI BERBAGAI NEGARA. Tesis thesis, Universitas Setia Budi Surakarta.
Text
bab 2.pdf Restricted to Registered users only Download (652kB) | Request a copy |
|
Text
bab 3.pdf Restricted to Registered users only Download (273kB) | Request a copy |
|
Text
bab 4.pdf Restricted to Registered users only Download (382kB) | Request a copy |
|
Text
bab 5.pdf Restricted to Registered users only Download (91kB) | Request a copy |
|
Text
bab 6-lampiran.pdf Restricted to Registered users only Download (158kB) | Request a copy |
|
Text
cover-bab 1.pdf Download (604kB) |
|
Text
intisari-abstrak.pdf Download (150kB) |
|
Text
lembar pernyataan publikasi.pdf Download (283kB) |
Abstract
Systematic review is a literature review method that identifies, assesses, interprets all findings of a research topic, to answer the research questions (reasearch question) that have been determined previously. This study aimed to determine the clinical goals of therapy and cost-effectiveness analysis of colorectal cancer metastase (mCRC) therapy used FOLFOX-6 and FOLFOX-6 combined with Bevacizumab® in various countries. This study used a Systematic review approach, which is a research method that identified, assessed and integrated all found regarding a research topic to address problems in a previously determined study. Systematic review in this study was carried out on the literature related to therapeutic analysis and the cost-effectiveness of mCRC treatment using FOLFOX-6 or FOLFOX-6 combined with Bevacizumab® in various countries. The search was carried out electronically using the PubMed and Embase databases. The results of this study indicate that mCRC therapy using FOLFOX-6 with the addition combination of bevacizumab® is better than FOLFOX-6 d in improves the quality of life of patients in a 5-20 years systematic review. ICER results on both FOLFOX-6 and FOLFOX-6 drugs with combination addition of Bevacizumab® to mCRC therapy in various countries showed that the addition of Bevacizumab® to FOLFOX-6 increased the cost to be more expensive but their use was more effective in healing and improving the quality of life of patients. Keyword: Systematic review, colorectal metastatic cancer, Bevacizumab®, FOLFOX, cost effectiveness analysis.
Item Type: | Thesis (Tesis) |
---|---|
Uncontrolled Keywords: | Systematic review, colorectal metastatic cancer, Bevacizumab®, FOLFOX, cost effectiveness analysis |
Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
Divisions: | Fakultas Farmasi > Prodi S2 Farmasi |
Depositing User: | Mrs NOVI HANDAYANI |
Date Deposited: | 13 Feb 2020 03:35 |
Last Modified: | 18 Sep 2020 03:29 |
URI: | http://repo.setiabudi.ac.id/id/eprint/4085 |
Actions (login required)
View Item |